GTDFX
Price
$32.87
Change
+$0.22 (+0.67%)
Updated
Dec 20 closing price
RNWFX
Price
$77.72
Change
+$0.12 (+0.15%)
Updated
Dec 20 closing price
Ad is loading...

GTDFX vs RNWFX

Header iconGTDFX vs RNWFX Comparison
Open Charts GTDFX vs RNWFXBanner chart's image
Invesco EQV Emerging Markets All Cap R6
Price$32.87
Change+$0.22 (+0.67%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$77.72
Change+$0.12 (+0.15%)
VolumeN/A
CapitalizationN/A
GTDFX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
GTDFX vs. RNWFX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GTDFX is a Hold and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 62.2B vs. GTDFX (1.41B). GTDFX pays higher dividends than RNWFX: GTDFX (1.92) vs RNWFX (1.51). GTDFX was incepted earlier than RNWFX: GTDFX (12 years) vs RNWFX (23 years). RNWFX is a more actively managed with annual turnover of: 32.00 vs. GTDFX (11.00). RNWFX has a lower initial minimum investment than GTDFX: RNWFX (250) vs GTDFX (1000000). RNWFX annual gain was more profitable for investors over the last year : 5.86 vs. GTDFX (1.98). RNWFX return over 5 years is better than : 14.39 vs. GTDFX (-8.08).
GTDFXRNWFXGTDFX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence12 years23 years-
Gain YTD0.7464.54916%
Front LoadN/AN/A-
Min. Initial Investment1000000250400,000%
Min. Initial Investment IRAN/AN/A-
Net Assets1.41B62.2B2%
Annual Yield % from dividends1.921.51128%
Returns for 1 year1.985.8634%
Returns for 3 years-8.39-5.10164%
Returns for 5 years-8.0814.39-56%
Returns for 10 years22.3042.6752%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VTRS12.520.39
+3.22%
Viatris
TEO11.890.14
+1.19%
Telecom Argentina SA
DX12.570.14
+1.13%
Dynex Capital
INTT7.680.04
+0.52%
inTEST Corp
VIRX0.21N/A
-1.87%
Viracta Therapeutics